Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NitroMed Hopes To Reach 35% Tier II Formulary Coverage For BiDil By End Of March

This article was originally published in The Pink Sheet Daily

Executive Summary

Tier II reimbursement is “critical” to success of the dual vasodilator for African-Americans with heart failure, company says.

You may also be interested in...

NitroMed's BiDil Approved For Heart Failure In Self-Identified Black Patients

The hydralazine/isosorbide dinitrate combination is the first approval for a race-based indication. In its recent review of BiDil, an FDA advisory committee suggested race was serving as a surrogate for genomic markers. FDA suggests further study could expand BiDil's approval beyond self-identified black patients.

Nexavar “Very Competitive” With Pfizer’s Sutent, Bayer Says

Bayer’s kidney cancer drug brought in $25.2 mil. (€20 mil.) in the first quarter following its approval late last year.

Nebivolol Approval Could Come In Mid-2007, Forest Says

The firm is conducting small studies of short duration after meeting with FDA regarding a May 2005 “approvable” letter.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts